Most Popular - Questcor Pharmaceuticals (QCOR) reported stellar earnings this week, topping analyst’s expectations for Acthar sales of $199.7 million by more than 15%: revenues in the quarter … Continue Reading
Read NowMost Popular - California-based Questcor Pharmaceuticals (QCOR) gave investors a case of whiplash Tuesday after reporting a fantastic quarter, yet following up with news about pending investigations into … Continue Reading
Read NowLong Ideas - After a negative vote from the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) and repeat signals that the regulatory agency was taking a hardline … Continue Reading
Read NowLong Ideas - Shares of Illumina (ILMN) have risen over 85% since our in-depth November 1, 2012 initiation of coverage, and for good reason: the company has, for … Continue Reading
Read NowMost Popular - On Thursday morning, Ziopharm Oncology (ZIOP) priced its recently announced secondary offering at $3.50 per share, a 30% discount to ZIOP’s $4.93 closing price on … Continue Reading
Read NowLong Ideas - Tekmira Pharmaceuticals (TKMR) announced a secondary offering on Wednesday and priced the deal before Thursday’s open. Tekmira is selling 3,750,000 common stock at a price … Continue Reading
Read NowLong Ideas - Early this year, Keryx Biopharmaceuticals (KERX) reported strong Phase III results for its phosphate binder Zerenex (ferric citrate) in dialysis patients, sending the stock from … Continue Reading
Read Now